KINETICS OF SALIVARY ELIMINATION OF CYCLOPHOSPHAMIDE IN MAN

被引:22
作者
JUMA, FD
ROGERS, HJ
TROUNCE, JR
机构
关键词
D O I
10.1111/j.1365-2125.1979.tb01025.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The concentrations of cyclophosphamide in plasma and saliva were determined in seven patients following administration of single doses of cyclophosphamide during chemotherapy for lymphoma. 2 The saliva/plasma ratio was 0.77 +/‐ 0.24 (s.d.) and showed no time‐ dependence being rapidly established following intravenous and oral administration. 3 The T 1/2 of cyclophosphamide (8.38 +/‐ 2.25 h) determined from salivary measurements was not significantly different from that in plasma (8.24 +/‐ 2.60 h). It was not possible to estimate the apparent volume of distribution or total body clearance utilizing the salivary cyclophosphamide concentration without appropriate correction for the saliva/plasma concentration ratio. 4 The binding to the plasma protein of normal plasma of cyclophosphamide was 13.4 +/‐ 5.3%. The Scatchard plot for binding to bovine serum albumin indicates only weak binding to non‐specific sites. 5 Salivary cyclophosphamide therefore indicates the concentration of the unbound fraction of plasma cyclophosphamide. 1979 The British Pharmacological Society
引用
收藏
页码:455 / 458
页数:4
相关论文
共 11 条
[1]  
BAGLEY CM, 1973, CANCER RES, V33, P226
[2]   THERAPEUTIC DRUG MONITORING IN SALIVA [J].
DANHOF, M ;
BREIMER, DD .
CLINICAL PHARMACOKINETICS, 1978, 3 (01) :39-57
[3]   MASS-SPECTROMETRIC STUDY OF DISTRIBUTION OF CYCLOPHOSPHAMIDE IN HUMANS [J].
DUNCAN, JH ;
COLVIN, OM ;
FENSELAU, C .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1973, 24 (02) :317-323
[4]  
GALEAZZI RL, 1976, CLIN PHARMACOL THER, V20, P278
[5]  
HORNING MG, 1977, CLIN CHEM, V23, P157
[6]  
JARDINE J, 1978, CANCER RESEARCH, V38, P408
[7]  
JUMA FD, 1978, CANCER CHEMOTH PHARM, V1, P229
[8]  
JUMA FD, BRIT J CLIN PHARMAC
[9]  
KOYSOOKO R, 1974, CLIN PHARMACOL THER, V15, P454
[10]   A SIMPLEX-METHOD FOR FUNCTION MINIMIZATION [J].
NELDER, JA ;
MEAD, R .
COMPUTER JOURNAL, 1965, 7 (04) :308-313